Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease by Kim, Yunjeong et al.
This is the author’s final, peer-reviewed manuscript as accepted for publication.  The 
publisher-formatted version may be available through the publisher’s web site or your 
institution’s library.  
This item was retrieved from the K-State Research Exchange (K-REx), the institutional 
repository of Kansas State University.  K-REx is available at http://krex.ksu.edu 
 
Potent inhibition of feline coronaviruses with peptidyl 
compounds targeting coronavirus 3C-like protease 
 
Yunjeong Kim, Sivakoteswara Rao Mandadapu, William C. Groutas, Kyeong-Ok Chang 
 
 
How to cite this manuscript 
 
If you make reference to this version of the manuscript, use the following information: 
 
Kim, Y., Mandadapu, S. R., Groutas, W. C., Chang, K.-O. (2013). Potent inhibition of 
feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease. 
Retrieved from http://krex.ksu.edu 
 
 
 
Published Version Information 
 
 
Citation: Kim, Y., Mandadapu, S. R., Groutas, W. C., Chang, K.-O. (2013). Potent 
inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like 
protease. Antiviral Research, 97(2), 161-168. 
 
 
Copyright: © 2012 Elsevier B.V. 
 
 
 
Digital Object Identifier (DOI): doi:10.1016/j.antiviral.2012.11.005 
 
 
 
Publisher’s Link: http://www.sciencedirect.com/science/article/pii/S0166354212002604 
 
 
 
1 
 
 
 
Potent Inhibition of Feline Coronaviruses with Peptidyl Compounds 
Targeting Coronavirus 3C-like Protease  
  
 
 
 
Yunjeong Kima, Sivakoteswara Rao Mandadapub, William C. Groutasb, Kyeong-Ok Changa 
 
 
a Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas 
State University, Manhattan, KS 66506, USA    
b Department of Chemistry, Wichita State University, Wichita, Kansas 67260, USA 
 
 
 
 
 
Corresponding author:  
 
Yunjeong Kim, DVM, PhD: Department of Diagnostic Medicine and Pathobiology, College of 
Veterinary Medicine, Kansas State University, 1800 Denison Avenue, Manhattan, KS 66506. E-
mail: ykim@vet.ksu.edu. Phone: (785) 532-4616.  Fax: (785) 532-4039.  
 
2 
 
Abstract 
Feline coronavirus infection is common among domestic and exotic felid species and usually 
associated with mild or asymptomatic enteritis; however, feline infectious peritonitis (FIP) is a 
fatal disease of cats that is caused by systemic infection with a feline infectious peritonitis virus 
(FIPV), a variant of feline enteric coronavirus (FECV). Currently, there is no specific treatment 
approved for FIP despite the importance of FIP as the leading infectious cause of death in 
young cats. During the replication process, coronavirus produces viral polyproteins that are 
processed into mature proteins by viral proteases, the main protease (3C-like [3CL] protease) 
and the papain-like protease. Since the cleavages of viral polyproteins are an essential step for 
virus replication, blockage of viral protease is an attractive target for therapeutic intervention. 
Previously, we reported the generation of broad-spectrum peptidyl inhibitors against viruses that 
possess a 3C or 3CL protease. In this study, we further evaluated the antiviral effects of the 
peptidyl inhibitors against feline coronaviruses, and investigated the interaction between our 
protease inhibitor and a cathepsin B inhibitor, an entry blocker, against a feline coronavirus in 
cell culture. Herein we report that our compounds behave as reversible, competitive inhibitors of 
3CL protease, potently inhibited the replication of feline coronaviruses (EC50 in a nanomolar 
range) and, furthermore, the combination of cathepsin B and 3CL protease inhibitors led to a 
strong synergistic interaction against feline coronaviruses in a cell culture system.  
 
 
Keywords: Feline coronaviruses; feline infectious peritonitis virus; protease inhibitor; cathepsin 
B; synergy; 3CL protease 
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1. Introduction 
Coronaviruses are single stranded positive sense RNA viruses that contain the largest 
non-segmented RNA virus genome. Coronaviruses are responsible for highly prevalent 
diseases in humans and animals, and are divided into the groups alpha, beta, and gamma, 
based on antigenic and genetic criteria, of which alpha and beta coronaviruses infect mammals 
(Homes, 2001). Severe acute respiratory syndrome coronavirus (SARS-CoV) is classified into 
the beta group of coronaviruses. Feline coronaviruses belong to alpha coronaviruses and affect 
animals in the family Felidae, including cheetahs, wildcats, lions and leopards (Heeney et al., 
1990; Kennedy et al., 2002). Feline coronavirus is further classified as serotype I or II. Feline 
serotype I and canine coronaviruses are considered to have originated from a common 
ancestor. Feline coronavirus serotype II appears to be derived from recombination with canine 
coronavirus and feline coronavirus serotype I in the S (spike) protein (Herrewegh et al., 1998; 
Motokawa et al., 1996). Feline coronavirus serotype I is more prevalent than serotype II, and 
feline coronaviruses of both serotypes can cause mild or asymptomatic enteritis and feline 
infectious peritonitis (FIP) in cats (Benetka et al., 2004; Kummrow et al., 2005; Pedersen et al., 
1984a). FIP is a fatal disease in cats and currently one of the leading infectious causes of 
fatality among young cats in multiple cat households and shelters (Pedersen, 2009). Feline 
enteric coronavirus (FECV) causes asymptomatic to mild enteritis among cats with a high 
prevalence (Pedersen et al., 2008; Vogel et al.). Unlike FECV which is confined to the intestinal 
epithelium, FIP virus (FIPV) gains ability to replicate in macrophages and monocytes by 
mutation of endogenous FECV and can spread through the entire body. The progression to FIP 
is also influenced by the host’s immune responses; a weak or defect in cell-mediated immune 
response is associated with the development of FIP (Pedersen, 2009). Despite the fatal nature 
and increasing incidence of FIP, no effective prophylactic or therapeutic agent is currently 
available for FIPV.  
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Coronaviruses have club-shaped S proteins on the envelope, which bind to the cells and 
undergo membrane fusion to gain entry into the cytoplasm. The cleavage of S proteins varies 
among coronaviruses. In some coronaviruses including SARS-CoV and murine hepatitis virus 
(MHV)-2, S proteins are cleaved by cellular cathepsins that are cysteine proteases typically 
present within the endosome/lysosome in the cell cytoplasm (Qiu et al., 2006; Simmons et al., 
2005). FIP and FECV are also found to be highly dependent on the presence of cathepsin B for 
the cleavage of their S proteins, which enables cell entry for virus replication (Regan et al., 
2008). The importance of the presence of cathepsin function in the replication of feline 
coronaviruses is demonstrated by the inhibition of some serotype I and II feline coronaviruses 
including WSU-1683, WSU-1146, and DF2 strains by a cathepsin B inhibitor CA074-Me and an 
irreversible non-specific cysteine inhibitor E64d by inhibiting the cleavage of S proteins (Regan 
et al., 2008). This result indicates that cathepsin B may serve as a potential target for the 
development of therapeutic drugs against feline coronaviruses.  
Following entry into the cells, coronaviruses express polyproteins (pp1a and pp1b), 
which are cleaved by viral proteases into intermediate and mature nonstructural proteins. The 
viral proteases involved in the cleavage of the polyproteins are papain-like proteases (PL1pro 
and PL2pro) and a 3C-like (3CL) protease. The papain-like proteases cleave the N-proximal 
region of pp1a/pp1ab, and 3CL protease cleaves the viral polyprotein at 11 conserved 
interdomain junctions (Ziebuhr et al., 2000). Coronavirus proteases, like many other viral 
proteases such as those of human immunodeficiency virus-1 and hepatitis C virus, for which 
commercial protease inhibitors are available, are highly effective regulators of virus replication. 
Coronavirus 3CL protease is a cysteine protease that shares common characteristics in 
structural and functional properties with the 3CL or 3C proteases of noroviruses and 
picornaviruses, respectively; they possess chymotrypsin-like folds, cysteine residue as a 
nucleophile, and conserved active sites. Viral 3CL or 3C protease plays an essential role in viral 
replication; consequently, it is an attractive target for the development of antiviral drugs. 
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Previously, we reported the generation of new peptidyl inhibitors against norovirus 3CL protease 
and their broad spectrum activity against viruses that possess 3C or 3CL proteases, including 
feline coronavirus (Kim et al., 2012; Tiew et al., 2011). In this study, we further studied the 
reversibility and the mode of inhibition of our 3CL protease inhibitors, and compared the antiviral 
effects of the 3CL protease inhibitors (GC373 and GC376) and cathepsin inhibitors against the 
replication of feline coronaviruses in cells. We also studied the combined antiviral effects of 
GC373 and CA074-Me, a cathepsin B inhibitor, against a feline coronavirus in cell culture. In 
summary, we have demonstrated that the peptidyl transition state inhibitors used in this study 
are reversible, competitive inhibitors of 3CL protease and potently inhibit the replication of feline 
coronaviruses in cell culture with an EC50 (the effective concentration for 50% inhibition of viral 
replication) in a nanomolar range. Furthermore, combined treatment of CA074-Me and GC373 
in cells exhibited a strong synergistic activity against a feline coronavirus. These results indicate 
that these 3CL protease inhibitors have a potential to be developed as antiviral drugs for feline 
coronaviruses as a single agent or in combination with an entry blocker.  
 
2. Materials and methods 
 
2.1. Compounds  
     GC373 and GC376 compounds were synthesized as previously described (Tiew et al., 2011) 
(Fig.1). Cathepsin B inhibitor CA074-Me [L-3-trans-((propylcarbamyl) oxirane-2-Carbonyl)-L-
isoleucyl-L-proline methyl ester] and a pan-cysteine cathepsin inhibitor E64d [(2S,3S)-trans-
epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester] were purchased from Calbiochem 
(Darmstadt, Germany). 
 
2.2. The expression and purification of transmissible gastroenteritis virus (TGEV) 3CL protease  
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     The 3CL proteases are highly conserved among all coronaviruses, and feline coronavirus 
3CL protease is closely related to TGEV 3CL protease (Hegyi et al., 2002) (Fig.2). Therefore, 
we cloned and expressed the TGEV 3CL protease for the fluorescence resonance energy 
transfer (FRET) assay. The cDNA encoding the full length of 3CL protease of TGEV Miller strain 
was amplified with RT-PCR as previously described (Anand et al., 2002). The primers contained 
the nucleotide sequence of the 3CL protease for cloning as well as the nucleotides for 6 
Histidine in the forward primer. The forward and reverse primers were TGEVPro-6hisXba-F 
(tctagaaaggagatataccatgcatcatcatcatcatcattcaggtttacggaaaatggc) and TGEVPro-Xho-
R(ctcgagtcactgaagatttacaccatac). The amplified product was subcloned to pET-28a(+) vector 
(GenScript, Piscataway, NJ). The expression and purification of the 3CL protease was 
performed with a standard method described previously by our lab (Chang et al., 2012b; 
Takahashi et al., 2012; Tiew et al., 2011). 
 
2.3. Enzymatic activity assay  
     3CL protease inhibitors, GC373 and GC376, and commercial cathepsin inhibitors, CA074-
Me and E64d, were prepared in DMSO as stock solutions (10 mM), and further diluted in assay 
buffer consisting of 20mM HEPES, 0.4 mM EDTA, 30% glycerol, 120 mM NaCl, and 4 mM DTT 
at pH 6. TGEV 3CL protease at a final concentration of 0.1~0.2 µM and the substrate (Edans-
Val-Asn-Ser-Thr-Leu-Gln/Ser-Gly-Leu-Arg-Lys[Dabcyl]-Met) (Kuo et al., 2004) at 10 µM were 
used for the studies. Compounds at various concentrations (0~50 µM) were pre-incubated with 
TGEV 3CL protease in 25 µl for 20 min at 37 °C, and the same volume of substrate was added 
to the mixture, or the compound was added to the protease immediately before the substrate 
was added to the enzyme/inhibitor mixture in 96-well black plate. The mixtures were then further 
incubated at 37 ºC for 60 min, and fluorescence readings were obtained on a microplate reader 
at 360 nm excitation and 480 nm emission wavelengths. The relative fluorescence units (RFU) 
were calculated by subtracting background (substrate control well without protease) from the 
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fluorescence readings. The dose-dependent FRET inhibition curves were fitted with variable 
slope (four parameters) using GraphPad Prism software 5 (La Jolla, CA) in order to determine 
the compound concentration that gives a half-maximum response (IC50). In separate 
experiments, TGEV 3CL protease (0.2 µM) was incubated with serially diluted GC373 (0~2 μM) 
in 25 μl of assay buffer and incubated at 37 ºC for 20 min, followed by the addition of various 
concentrations of substrates (10~200 μM). The mixtures were incubated at 37 ºC, and 
fluorescence readings were obtained on a microplate reader at every 5 min for up to 30 min. 
The correction factors to compensate for the inner filter effects were determined empirically as 
described previously (Chang et al., 2012b; Cuerrier et al., 2005; Jaulent et al., 2007). The 
kinetic constant Km was determined by the fitting initial rates to the Michaelis-Menten equation 
using GraphPad Prism software. Lineweaver-Burk plots were constructed using GraphPad 
Prism software to determine Ki values as well as the type of enzyme inhibition. Lastly, recovery 
of enzymatic activity of TGEV 3CL protease over time (rapid dilution experiments) was studied 
to demonstrate reversible binding of GC373 to TGEV 3CL protease (Copeland, 2005; Xie et al., 
2011). Rapid dilution experiments were performed by incubating TGEV 3CL protease at 100 
times the concentration that is normally used in a reaction with DMSO or GC373 at 
concentrations approximately 10 times greater than the IC50 value (10 μM) for 30 min at 37 °C. 
After incubation, the mixture was diluted 100-fold in reaction buffer to normal reaction condition 
before the substrate was added. The fluorescence readings were obtained on a microplate 
reader over time, and the progress curves were generated.   
 
2.4. Cells, viruses, and reagents  
     Crandell Rees feline kidney (CRFK) cells were maintained in minimal essential medium 
containing 2-5% fetal bovine serum and antibiotics (chlortetracycline [25 µg/ml], penicillin [250 
U/ml], and streptomycin [250 µg/ml]). Cell culture-adapted feline coronaviruses WSU 79-1146 
and WSU 79-1683 strains were purchased from ATCC (Manassas, VA).  
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2.5. Antiviral effects of the protease and cathepsin inhibitors against feline coronaviruses in cells 
     Virus infection was performed as follows: solvent (0.1% DMSO), CA074-Me, E64d, GC373 
or GC376 was added at various concentrations to two-day old monolayers of CRFK cells 
prepared in 6 well plates. The cells were further incubated in the presence of each compound or 
solvent for 2 h at 37 °C, or the compound was added at the same time with virus inoculation. 
WSU-1147 or WSU-1683 was inoculated to the cells at a multiplicity of infection (MOI) of 0.05 or 
5 (MOI 5 for Western blot analysis). The virus infected cells were incubated in the presence of a 
compound for up to 2 days, and EC50 was determined by the TCID50 method (Reed and 
Muench, 1938).  
 
2.5.1. Western blot analysis  
     Cell lysates from CRFK cells were prepared by adding sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer containing 2% β-
mercaptoethanol and sonication for 20 sec. The proteins were then resolved in a 10% Novex 
Bis-Glycin gel (Invitrogen, Carlsbad, CA) and transferred to a nitrocellulose membrane. The 
transferred nitrocellulose membranes were incubated with primary antibodies to coronavirus 
nucleocapsid protein (Biocompare, Windham, NH) or β-actin as a loading control overnight, and 
then with the secondary antibodies conjugated with peroxidase for 2 h. Following incubation 
with a chemiluminescent substrate (SuperSignal West Pico Chemiluminescent Substrate, 
Pierce biotechnology, Rockford, IL), the signals were detected on X-ray films.    
 
2.5.2. TCID50 method  
     A standard TCID50 method with the 10-fold dilution of each sample was used for virus 
titration (Reed and Muench, 1938).   
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2.5.3. Nonspecific cytotoxic effect  
     We determined the toxic concentration for 50% cell death (TC50) for each compound in 
CRFK cells. Confluent cells grown in 24-well plates were treated with various concentrations of 
compounds at up to 100 µM for cathepsin inhibitors and 500 µM for 3CL protease inhibitors for 
24 or 48 h. Cell cytotoxicity was measured by a CytoTox 96® non-radioactive cytotoxicity assay 
kit (Promega, Madison, WI) and crystal violet staining. The in vitro therapeutic index (TI) was 
calculated by dividing TC50 by EC50.  
 
2.6. Combination treatment of a cathepsin B inhibitor, CA074-Me, and GC373  
     The CRFK cells were incubated with GC373 (0.02~0.2 μM), CA074-Me (0.5~5 μM), or the 
combinations of GC373 (0.02~0.2 μM) and CA074-Me (0.5~5 μM) for 2 h at 37 °C, prior to 
inoculation of WSU-1146 at an MOI of 0.05. After 24 h of incubation, virus replication was 
assessed with virus titration using the TCID50 method. Drug-drug interactions were analyzed by 
the three-dimensional model of Prichard and Shipman (Prichard and Shipman, 1990), using the 
MacSynergy II software at 95% confidence limits. Theoretical additive interactions were 
calculated from the dose-response curve for each compound individually, and the calculated 
additive surface was subtracted from the experimentally determined dose-response surface to 
give regions of synergistic or antagonistic interactions. The resulting surface appears as 
horizontal plane at 0% of synergy if the interactions of two compounds are additive. Any peak 
above or below this plane indicates synergy or antagonism, respectively. 
 
3. Results  
 
3.1. Effects of the 3CL protease inhibitors on the protease activity in the FRET-based assay  
     The protease inhibition assay was performed using the florescence substrate derived from a 
cleavage site of SARS-CoV to examine the inhibition of the 3CL protease by GC373 and 
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GC376. The inhibitory effects of each compound at 50 µM (final concentration) on the activity of 
TGEV 3CL protease are shown in Fig.3A. Cathepsin B inhibitor CA074-Me and pan-cysteine 
cathepsin inhibitor E64d were included as controls. GC373 and GC376 remarkably inhibited the 
activity of TGEV 3CL protease at 50 µM, but the cathepsin inhibitors did not (Fig.3A). The dose-
dependent inhibition of TGEV 3CL protease activities by GC373 with or without pre-incubation 
of the compound with the protease is shown by open circles and filled squares, respectively, in 
Fig.3B. The IC50 values of GC373 and GC376 against the 3CL protease determined in the 
FRET assay were 0.98 μM and 0.82 μM, respectively, when the compounds were pre-incubated 
with the protease. The IC50 values of GC373 and GC376 against the 3CL protease without pre-
incubation were 3.2 μM and 2.7 μM, respectively, indicating that pre-incubation of the protease 
with the 3CL inhibitors caused about a three-fold increase in inhibitor potency. The Km value for 
the fluorogenic substrate was 15.52 μM. The Lineweaver–Burk plots (Fig.3C) suggested 
competitive inhibition of the proteolytic cleavage of the substrate by GC373 with a Ki value of 
0.43 ± 0.06 μM. Reversibility of our compound was determined by the rapid dilution experiments. 
As shown in Fig.3D, the enzymatic activity of the 3CL protease incubated with GC373 at 10 x 
IC50 concentration recovered after 100-fold dilution of the protease/inhibitor mixture. At the final 
concentration after the dilution, the inhibitor concentration is 10-fold below the IC50. The recovery 
of enzymatic activity over time indicates that the compound was a reversible inhibitor.  
 
3.2. Effects of the 3CL protease inhibitors and cathepsin inhibitors against the replication of 
feline coronaviruses in cells  
     The antiviral effects of the 3CL protease inhibitors and cathepsin inhibitors were studied in 
cell culture. The replication of WSU-1683 and WSU-1146 were markedly inhibited by the 
presence of GC373, GC376, CA074-Me, or E64d (Tables 1 and 2, Fig.4). However, 
suppression of virus replication by the 3CL protease inhibitors was more potent than those by 
CA074-Me and E64d at 24 and 48 h, indicated by the EC50 values (Table 1). Notably, the 
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antiviral activities of CA074-Me and E64d decreased substantially over time (Table 1). When the 
3CL protease inhibitors were added to the cells at the same time of virus infection, the EC50 
values of the compounds increased by 2- to 3.75-fold, compared to those obtained from pre-
incubation of cells with the compounds (Table 2). The antiviral effects of the 3CL protease 
inhibitors were selective; they were not active against unrelated viruses such as influenza virus 
and porcine respiratory and reproductive syndrome virus (data not shown). The antiviral activity 
of GC373 and GC376 was not due to nonspecific cytotoxicity, since the 3CL protease inhibitors 
did not show any cytotoxicity in various cells even at 500 µM. The cathepsin inhibitors CA074-
Me and E64d also did not show any toxicity at 100 µM. The in vitro therapeutic indices 
calculated from the ratio of EC50/TC50 of cathepsin and 3CL protease inhibitors are at least 25 
and 2900, respectively, at 24 h post virus infection. These results demonstrate that the 
replication of feline coronaviruses is effectively inhibited by the 3CL protease inhibitors with an 
excellent safety margin in cells.  
 
3.3. Effects of the combined treatment of GC373 and CA074-Me in the replication of WSU-1146  
     Combination treatment of GC373 and CA074-Me was performed to investigate the 
interactions of the two compounds with different modes of inhibition against the replication of 
WSU-1146. The effects of combination were determined to be strongly synergistic, as analyzed 
in a mathematical model based on the MacSynergy. Antiviral synergy was observed between 
GC373 and CA074-Me with an average Synergy95 volume of 99.3 µM2% at a 95% confidence 
interval over two experiments (Fig.5A and B, and Table 3). Absolute values over 25 µM2% 
indicate significant values of synergy. For example, when virus-infected CRFK cells were 
treated with GC373 at 0.05 µM or CA074-Me at 1 µM, each resulted in a 0.5 log10 reduction of 
virus titers; in contrast, the combination of the two led to a 2 log10 viral titer reduction, which was 
much more effective than either compound alone (indicated as synergy % in Table 3).  
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4. Discussion 
 
Feline infectious peritonitis is believed to be caused by infectious peritonitis virus arising 
by changing tissue tropism from intestinal cells to macrophages by mutations of feline enteric 
coronavirus in individual cats (Chang et al., 2012a; Vennema et al., 1998). The underlying 
mechanisms that allow the tissue tropism change is reported to be associated with mutations in 
the S and open reading frame 3c genes and the aberrant immune response of the host, but the 
detailed mechanism of the altered tropism has not been clearly established (Chang et al., 2012a; 
Chang et al., 2011; Pedersen et al., 2012; Poland et al., 1996; Vennema et al., 1998). The feline 
enteric coronaviruses are present ubiquitously in the environment and easily transmitted via a 
fecal-oral route. Thus elimination of feline coronavirus from multi-cat environments can be 
challenging. Although therapeutic measures for FIP are highly desirable to control this fatal 
disease, limited information on the effective treatment for FIP is available (Legendre and 
Bartges, 2009; Ritz et al., 2007). The general treatment options for FIP are supportive therapy, 
including the use of immunosuppressants such as glucocorticoids, and antibiotics (Hartmann 
and Ritz, 2008). Other agents that have been used include interferons, tumor necrosis factor-α 
inhibitor, propentofylline, and polyprenyl immunostimulant (Ishida et al., 2004; Legendre and 
Bartges, 2009; Ritz et al., 2007). However, the therapeutic efficacy of those immune modulating 
agents was shown to be ineffective or needs further investigation in controlled trials (Fischer et 
al., 2011; Ritz et al., 2007). Ribavirin was reported to reduce the replication of FIPV with an IC50 
of 10 μM and a TC50 of 69 μM, and a later study using specific pathogen free cats infected with 
FIPV showed that ribavirin treatment at 16.5 mg/kg was not effective at reducing fatality or 
severity of symptoms (Weiss et al., 1993). In addition, studies on the antiviral agents that 
directly or indirectly target virus components and/or replication steps are very limited (Barlough 
and Shacklett, 1994; Hsieh et al., 2010).   
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Our group has previously reported a series of new 3CL protease inhibitors targeting the 
3CL protease of norovirus (Tiew et al., 2011). Coronavirus 3CL protease is classified as a 
chymotrypsin-like cysteine protease and shares a remarkable degree of conservation of the 
active site with norovirus 3CL protease. Our dipeptidyl 3CL protease inhibitors incorporate in 
their structure a glutamine surrogate and a leucine residue that correspond to the P1 and P2 
sites in the substrate (Tiew et al., 2011). The amino acid residues in the substrate are 
designated as P1, P2, etc., starting at the scissile bond and counting towards the N-terminus. 
Likewise, the amino acid residues reside on the C-terminus side of the scissile bond are 
designated as P1’, P2’, etc (Schechter and Berger, 1967). The 3CL protease inhibitors were 
originally developed by our group by reflecting the substrate specificity of norovirus 3CL 
protease where the most frequently found residues in the P1 and P2 positions at the cleavage 
sites are glutamine and leucine, respectively. These amino acid residues in the P1 and P2 sites 
are also conserved among coronaviruses, including TGEV, FECV, FIPV, MHV, and human 
coronaviruses (Hegyi and Ziebuhr, 2002; Yang et al., 2005). These highly conserved features 
among viruses encoding 3C or 3CL proteases led to the finding that our dipeptidyl compounds 
potently inhibit the replication of noroviruses, picornaviruses, and coronaviruses including feline 
coronaviruses in cells (Kim et al., 2012). These peptidyl compounds were previously 
demonstrated to target coronavirus 3CL protease by the FRET protease assay and the crystal 
structure of TGEV 3CL protease-GC376 complex (Kim et al., 2012). GC373 possesses 
aldehyde as a potent electrophile that reacts with a cysteine (the nucleophilic sulfur) in the 
active site of virus protease in a reversible manner, and the bisulfite adduct warhead of GC376 
was synthesized from the precursor aldehyde (Fig.1). Since the bisulfite adduct is converted to 
the aldehyde form to form a covalent bond with cysteine in the active site of virus protease, 
based on the preliminary results in rats and the crystal structure of the complex of GC376 and 
TGEV 3CL protease, it is likely that GC376 behaves as a prodrug of the aldehyde counterpart 
(Kim et al., 2012).  
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In this study, we compared the antiviral activities of our dipeptidyl compounds and a 
cathepsin B inhibitor CA074-Me and non-specific cysteine cathepsin inhibitor E64d against 
feline coronaviruses WSU-1683 and WSU-1146. Both virus strains are cell culture adapted type 
II feline coronaviruses, of which WSU-1146 is confirmed to cause FIP in experimental settings 
(Pedersen et al., 1984b). WSU-1683 was originally thought to be a feline enteric coronavirus 
since it induced inapparent to mild enteritis without causing systemic infection in experimentally 
infected cats (Pedersen et al., 1984b). However, the subsequent sequence analysis studies on 
the mutations of genes that may contribute to development of FIPV from FECV suggest that 
WSU-1683 may have lost its virulence as FIPV and reverted to FECV biotype (Chang et al., 
2010; Herrewegh et al., 1995; Pedersen, 2009; Pedersen et al., 2008). In our study, cathepsin 
inhibitors CA074-Me and E64d significantly inhibited the replication of feline coronaviruses at 24 
h, although their potency was 13~100-fold lower than that of the 3CL protease inhibitors. 
However, a rapid loss of activity of CA074-Me and E64d was observed over time in cell culture 
without daily addition of the compounds, compared to the 3CL protease inhibitors. The shorter 
duration of the activity of cathepsin inhibitors against viral replication is speculated to be viruses 
overcoming the antiviral blockade imposed by inhibition of cathepsin activity by resynthesis of 
uninhibited cathepsins or the relative instability of the cathepsin inhibitors in media. The antiviral 
effects of non-specific cathepsin inhibition by E64d against feline coronaviruses were more 
potent than the inhibition by cathepsin B at 24 h post infection, which may be explained by 
differences in affinity for the protease, stability of compounds, or potential presence of 
cathepsins other than cathepsin B that are able to process the viral polyproteins. It was reported 
previously that FIPV and FECV differ in their requirement of cathepsins for the cleavage of S 
protein to gain entry into cells; both cathepsin B and L are required for FECV, but cathepsin L is 
dispensable for FIPV strains in cells (Regan et al., 2008), suggesting the different requirement 
for cathepsins among the virus strains. When our 3CL protease inhibitors were added to the 
cells at the same time of virus infection, the antiviral activity of the compounds was reduced, 
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compared to 2 h pre-incubation of the cells with the inhibitors, reflected by the increase of the 
EC50 values by up to 3.7-fold. In the FRET assay, the IC50 values of GC373 and GC376 against 
the 3CL protease also increased by about 3-fold. However, the antiviral activities of GC373 and 
GC376 in cells were still potent with nanomolar EC50 values, even when the inhibitors were 
added to the cells at the time of virus inoculation.  
Our X-ray crystallographic studies previously showed that GC376 binds to the active site 
and forms a reversible covalent bond with a cysteine residue in the active site of 3C or 3CL 
proteases of Norwalk virus, poliovirus, and TGEV (Kim et al., 2012). In this study, the kinetic 
analysis of TGEV 3CL protease and GC373 revealed the reversible, competitive nature of the 
inhibitor. We have not examined our 3CL protease inhibitors against the serotype I feline 
coronaviruses for their antiviral activities in this study. However we expect the 3CL protease 
inhibitors to be effective against serotype I feline coronaviruses since the 3CL protease is 
conserved among coronaviruses, and the 3CL protease inhibitors also inhibited the replication 
of TGEV and MHV in our previous study (Kim et al., 2012). 
Since our 3CL protease inhibitors and CA074-Me act on different targets, we 
subsequently investigated the effects of the combined treatment of GC373 and CA074-Me 
against a feline coronavirus in cells. The analysis of the drug-drug combination at the 95% 
confidence interval by MacSynergy software showed the synergy volume of 99.3 µM2%. Only 
small volume of antagonism (-5.79 µM2%) was observed when a high concentration of CA074-
Me (5 µM) were added to the cells containing GC373 (Fig.5, Table 3). At high concentrations, 
synergic activity was reduced as the antiviral response by single treatment reached high, and 
the synergy was most evident at mid range of compound concentrations used. We found no 
significant synergy of drug cytotoxic effects at the concentrations used. Our results showed the 
entry blocker and the protease inhibitor that work at the different stages of virus life cycle act 
synergistically at the concentrations shown. The favorable drug-drug interactions observed with 
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a feline coronavirus suggest a potential use of combination of compounds that target the host 
factor involved in virus entry and the virus protease for feline coronavirus infection.  
In summary, the 3CL protease inhibitors used in this study were found to be highly 
effective against feline coronaviruses in cells and the antiviral effects of those 3CL protease 
inhibitors were more profound than inhibition of cathepsins. Strong synergic effects were 
observed in combination treatment of a cathepsin B inhibitor and our 3CL protease inhibitor. 
These findings underscore the effectiveness of our 3CL protease inhibitors for feline coronavirus 
infection and potential use of 3CL protease inhibitors as a single therapeutic agent or in 
combination with cathepsin B inhibitors.   
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Fig.1. (A) Dipeptidyl protease inhibitors, GC373 and GC376. (B) Proposed mechanism of 
transition state inhibition of 3CL protease by GC373. 
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Fig.2. The sequence alignment of the 3CL protease of TGEV (Miller strain) and feline 
coronaviruses (WSU-1146 and DF2 strains). Asterisks mark the position of the conserved 
cysteine (144) and histidine (41) residues in the active site. 
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Fig.3. FRET-based protease assay. A. The effects of the 3CL protease inhibitors, GC373 and 
GC376, a cathepsin B inhibitor CA074-Me, and a pan-cysteine cathepsin inhibitor E64d on the 
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activity of TGEV 3CL protease in the FRET-protease assay. TGEV 3CL protease was incubated 
with each compound at 50 μM for 20 min before the substrate was added to the mixture. Each 
bar represents the percent relative fluorescence (mean ± standard error of the mean [SEM]). B. 
A plot of log
10
 GC373 concentration versus percent maximal response. TGEV 3CL protease 
was incubated with GC373 for 20 min at increasing concentrations prior to addition of substrate 
(open circles), or GC373 was added at the same time with the substrate (filled squares). The 
fluorescence signals were detected by a spectrophotometer, and the data are then plotted as 
percent maximal response against the log concentrations of the compound. The data points 
represent the percent maximal response (mean ± SEM). C. Lineweaver-Burk plots of kinetic 
data of the TGEV 3CL protease incubated with various concentrations of GC373. The 
enzymatic activities were measured using 10-200 µM substrate in the absence (filled circles) or 
presence of 0.5 (filled triangles), 1 (filled diamonds), and 2 (open diamonds) µM GC373. D. 
Progress curves for the recovery of enzymatic activities of TGEV 3CL protease after 3CL 
protease-GC373 complex was rapidly diluted to the normal assay solution. TGEV 3CL protease 
was incubated with DMSO (filled diamonds) or 10 µM (open circles) GC373 for 20 min, then 
rapidly diluted 100-fold in reaction buffer prior to substrate addition, and assayed for enzymatic 
activity.  
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Fig.4. Western blot analysis of the effects of GC373, GC376, and CA074-Me on the 
accumulation of coronavirus nucleocapsid proteins in CRFK cells infected with WSU-1146.  
CRFK cells were treated with 0.1% DMSO, GC373, GC376, or CA074-Me for 2 h, followed by 
virus infection at an MOI of 5, and further incubated for 12 h. Cell extracts were analyzed by 
Western blot for expression of coronavirus nucleocapsid protein and β-actin was loaded as an 
internal control. Numbers below each lane indicate the values of coronavirus nucleocapsid 
proteins normalized to β-actin obtained with densitometric scanning using TotalLab Quant 
software (TotalLab LtD).  
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Fig.5. Three-dimensional plots showing the interaction of GC373 and CA074-Me on the 
replication of WSU-1146. A and B. CRFK cells were incubated with CA074-Me (0.5~5 µM), 
GC373 (0.02~0.2 µM) or combinations of CA074-Me and GC373 for 2 h before the virus was 
inoculated in the cells at an MOI of 0.05. The cells were further incubated in the presence of 
each compound for 24 h, and virus replication was measured by the TCID
50
 method. Drug-drug 
interactions were analyzed by the three-dimensional model of Prichard and Shipman, using the 
MacSynergy II software at a 95% confidence interval. Surface above the plane of 0% synergy in 
the plot indicate synergy. B. Contour plots (two-dimensional representations of the data) for 
easier identification of the concentration ranges where statistically significant synergistic or 
antagonistic effects occurred. 
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Table 1. The effects of GC373, GC376, CA074-Me and E64d on the replication of feline 
coronaviruses in CRFK cells pre-incubated with the compounds.  
 
 
 
* The mean and standard error of the mean (SEM) of the EC
50
 values for virus inhibition at 24 and 48 hr 
post infection are summarized. CRFK cells were incubated with each compound for 2 hrs before virus 
infection at an MOI of 0.05 and further incubated in the presence of each compound for up to 48 hrs. 
Virus titers were determined using the TCID
50
 method for the calculation of the EC
50
 values.  
 
Table 2. The effects of GC373 and GC376 on the replication of feline coronaviruses in CRFK 
cells without pre-incubation.  
 
 
 
 
* The mean and standard error of the mean (SEM) of the EC
50
 values for virus inhibition at 24 hr post 
infection are summarized.  Each compound was added to CRFK cells at the same time with virus 
inoculation at an MOI of 0.05, and further incubated in the presence of each compound for up to 24 hrs. 
Virus titers were determined using the TCID
50
 method for the calculation of the EC
50
 values.  
  
 
Inhibition against feline coronaviruses * 
WSU-1683 WSU-1146 
 
24 hrs 48 hrs 24 hrs 48 hrs 
GC373 0.04 ± 0.01 0.09 ± 0.01 0.07 ± 0.04 0.43 ± 0.35 
GC376 0.17 ± 0.11 0.28 ± 0.10 0.15 ± 0.05 0.30 ± 0.10 
CA074-Me 4.0 ± 0.71 >10 2.5 ± 1.4 >10 
E64d 2.3 ± 0.28 >10 1.45 ± 0.49 >10 
 Inhibition [EC
50 
(µM)] against feline coronaviruses * 
 
 
WSU-1683 WSU-1146 
GC373 0.15 ± 0.18 0.12 ± 0.09 
GC376 0.40 ± 0.21 0.30 ± 0.14 
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Table 3. Summary of MacSynergy analysis on the combination effects of GC373 and CA074-Me 
against the replication of FIPV-1146 in CRFK cells.  
 
 
 
CA074-Me 
(µM) 
GC373 (µM) 
Synergy 
volume at 
95% CI 
(µM
2
%)* 
Antagonism 
volume at 
95% CI 
(µM
2
%) 
0 0.02 0.05 0.1 0.2  
 
 
 
 
 
 
99.3 
 
 
 
 
 
 
 
-5.79 
5 0 -5.78 1.87 0 -0.0004 
2 0 31.45 25.23 1.94 0 
1 0 0 28.95 2.56 0 
0.5 0 n/a 7.28 0 0 
0 0 0 0 0 0 
 
 
* Synergy/antagonism volumes were calculated at the 95% confidence level.  
 
 
